Abstract
Induced pluripotent stem cells (iPSCs) share many characteristics with embryonic stem cells (ESCs), but circumvent most of the ethical issues surrounding ESCs. The use of iPSCs to treat liver diseases is gaining increasing interest. Recent studies show these iPSCs can be differentiated into the hepatic lineage and provide an accurate model for liver diseases, drug screening and drug toxicity testing. Recently, the potential application of iPSC-derived hepatocytes to be used in cell-based therapies has been explored as a novel strategy to treat human liver disease. However, the successful use of these iPSC-derived hepatocytes hinges on overcoming the inherent problems of using iPSC in cell-based therapies. Given these problems are addressed in the future, these iPSC derived hepatocytes provide a limitless supply of cells that could be used to treat liver diseases not only in screening and toxicity testing but also in cell-based therapies.
Keywords: Bio-artificial liver, cell-based therapy, disease modeling, drug screening, hepatocyte-like cells, induced pluripotent stem cells, liver disease.
Current Stem Cell Research & Therapy
Title:Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research
Volume: 10 Issue: 3
Author(s): Chao Sun, George S. Wilson, Jian-Gao Fan and Liang Qiao
Affiliation:
Keywords: Bio-artificial liver, cell-based therapy, disease modeling, drug screening, hepatocyte-like cells, induced pluripotent stem cells, liver disease.
Abstract: Induced pluripotent stem cells (iPSCs) share many characteristics with embryonic stem cells (ESCs), but circumvent most of the ethical issues surrounding ESCs. The use of iPSCs to treat liver diseases is gaining increasing interest. Recent studies show these iPSCs can be differentiated into the hepatic lineage and provide an accurate model for liver diseases, drug screening and drug toxicity testing. Recently, the potential application of iPSC-derived hepatocytes to be used in cell-based therapies has been explored as a novel strategy to treat human liver disease. However, the successful use of these iPSC-derived hepatocytes hinges on overcoming the inherent problems of using iPSC in cell-based therapies. Given these problems are addressed in the future, these iPSC derived hepatocytes provide a limitless supply of cells that could be used to treat liver diseases not only in screening and toxicity testing but also in cell-based therapies.
Export Options
About this article
Cite this article as:
Sun Chao, S. Wilson George, Fan Jian-Gao and Qiao Liang, Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research, Current Stem Cell Research & Therapy 2015; 10 (3) . https://dx.doi.org/10.2174/1574888X10666150120105946
DOI https://dx.doi.org/10.2174/1574888X10666150120105946 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep and the Immune System
Current Immunology Reviews (Discontinued) Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Proteolytic Events of HIV-1 Replication as Targets for Therapeutic Intervention
Current Pharmaceutical Design Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathophysiological Mechanisms of Stress-Induced Intestina Damage
Current Molecular Medicine Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs
Current Medicinal Chemistry Cholesterol Efflux and Reverse Cholesterol Transport: Experimental Approaches
Current Medicinal Chemistry Shear Stress-sensitive Carriers for Localized Drug Delivery
Current Pharmaceutical Design Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Preface
Current Molecular Medicine Analysis of NCL Proteins from an Evolutionary Standpoint
Current Genomics Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science Hormones and their Receptors Bridge Fat and Bone Metabolisms
Current Signal Transduction Therapy